VLA 0.00% $1.75 viralytics limited

Ann: VLA to Present CAVATAK Clinical Data at Upcoming Conferences-VLA.AX, page-2

  1. 891 Posts.
    lightbulb Created with Sketch. 117
    Interesting 'poster' heading (p2), seems to allude some positive P2-CALM updates, good news...

    'Phase II CALM Extension study: Intratumoural Coxsackievirus A21 increases immune-cell infiltrates and up-regulates immunecheckpoint molecules in the tumour micro-environment'

    Bring on mid-October...

    ML
 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.